←
Ubiquigent275 posts
Ubiquigent avatar

Ubiquigent

@ubiquigent

Ubiquigent enables the discovery and development of novel #deubiquitinase (DUB) modulators as powerful new #therapeutics

◷ Joined February 2012▧ 111 Photos and videos
Ubiquigent avatar
Ubiquigent@ubiquigent·30 May 2025

We are in the process of transferring the Ubiquigent brand to a new owner, who may, in due course, provide future support to UPS research worldwide. We wish you all well with your future research and scientific endeavours.

Ubiquigent avatar
Ubiquigent@ubiquigent·30 May 2025

To all our valued customers, collaborators, partners and suppliers, we regret to inform you that Ubiquigent Limited is no longer providing access to high-quality, validated reagents or services to support your Ubiquitin Proteasome System (UPS) related research.

Ubiquigent avatar
Ubiquigent@ubiquigent·19 Mar 2025

@o2h_discovery will provide Ubiquigent with access to chemists and associated expertise to support its development of a novel portfolio of DUB-targeting compounds to enable the development of DUB-based therapeutics in partnership with its pharma and biotech partners.

Ubiquigent avatar
Ubiquigent@ubiquigent·21 Jan 2025

Last call to submit to our DUBprofiler Open Access Initiative! Submit your DUB inhibitors for screening - gain insights into your non-proprietary compounds’ potency & selectivity to ensure your research & #drugdiscovery programmes have a strong foundation: services@ubiquigent.com

Post attachment
Ubiquigent avatar
Ubiquigent@ubiquigent·7 Jan 2025

Interested in learning more about the potency & selectivity of your compounds? Join our DUBprofiler Open Access Initiative & submit non-proprietary DUB modulators for screening against our gold standard #assay before 31 Jan. 💻 bit.ly/4f8GDOP 📩 services@ubiquigent.com

Post attachment
Ubiquigent avatar
Ubiquigent@ubiquigent·10 Dec 2024

📢Ubiquigent launches DUBprofiler Open Access Initiative Many #DUB inhibitors in the public domain have inadequately characterised selectivity. To counter this, we're inviting scientists to submit non-proprietary compounds for characterisation at no cost: bit.ly/4f8GDOP

Post attachment
Ubiquigent avatar
Ubiquigent@ubiquigent·19 Nov 2024

Using DUBprofiler-Cell and DUBprofiler-Tissue, we supported a partner to determine target engagement & selectivity of their compound in biochemical, cell-based and preclinical animal studies. 📄Read more: rb.gy/3oo82

Ubiquigent avatar
Ubiquigent@ubiquigent·19 Nov 2024

It’s great to see more and more exciting companies working in the DUB space! 🤝 Mid-Atlantic BioTherapeutics and @AcceleroB combine neurological #drugdiscovery and high-throughput protein X-ray crystallography based fragment screening to develop USP30 inhibitors for Parkinson’s.

Post attachment
Ubiquigent avatar
Ubiquigent@ubiquigent·7 Nov 2024

USP30 is a DUB enzyme which is an actionable drug target for diseases associated with mitochondrial dysfunction, including Parkinson’s disease, with many companies exploring opportunities for USP30 inhibition.

Post attachment
Ubiquigent avatar
Ubiquigent@ubiquigent·5 Nov 2024

#BIOEurope has kicked off, bringing together industry leaders to discuss the future of biotech. Our team have a busy week ahead, meeting with partners, customers, and potential investors to share insights into our novel approach to DUB-focused #drugdiscovery.📩info@ubiquigent.com

Post attachment
Ubiquigent avatar
Ubiquigent@ubiquigent·31 Oct 2024

Next week, Hozefa Amijee and Rishi Shah will be at #BIOEurope,discussing how we are using our industry-leading platform to build a portfolio of novel DUB-targeting compounds to accelerate our partners’ programmes. Learn more: 💻ubiquigent.com 📩 Info@ubiquigent.com

Post attachment